CN112063541B - 一种加氏乳杆菌tci515用于制备免疫调节组合物的用途 - Google Patents
一种加氏乳杆菌tci515用于制备免疫调节组合物的用途 Download PDFInfo
- Publication number
- CN112063541B CN112063541B CN201910777548.XA CN201910777548A CN112063541B CN 112063541 B CN112063541 B CN 112063541B CN 201910777548 A CN201910777548 A CN 201910777548A CN 112063541 B CN112063541 B CN 112063541B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus gasseri
- composition
- strain
- cells
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000007365 immunoregulation Effects 0.000 title abstract description 4
- 230000014509 gene expression Effects 0.000 claims abstract description 34
- 230000015788 innate immune response Effects 0.000 claims abstract description 13
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000002158 endotoxin Substances 0.000 claims description 22
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 22
- 108090000171 Interleukin-18 Proteins 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 11
- 102000003810 Interleukin-18 Human genes 0.000 claims description 10
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 230000028709 inflammatory response Effects 0.000 claims description 9
- 108090001007 Interleukin-8 Proteins 0.000 claims description 8
- 239000003833 bile salt Substances 0.000 claims description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 6
- 102000004890 Interleukin-8 Human genes 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 3
- 229940096397 interleukin-8 Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 239000002207 metabolite Substances 0.000 abstract description 16
- 230000001580 bacterial effect Effects 0.000 abstract description 9
- 244000005700 microbiome Species 0.000 abstract description 8
- 108090000695 Cytokines Proteins 0.000 abstract description 7
- 230000000770 proinflammatory effect Effects 0.000 abstract description 7
- 102000004127 Cytokines Human genes 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 239000006041 probiotic Substances 0.000 abstract description 4
- 230000000529 probiotic effect Effects 0.000 abstract description 4
- 235000018291 probiotics Nutrition 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 42
- 239000006143 cell culture medium Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 14
- 239000012228 culture supernatant Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000003753 real-time PCR Methods 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 101150087698 alpha gene Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102100028183 Cytohesin-interacting protein Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000916686 Homo sapiens Cytohesin-interacting protein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明是涉及微生物领域，特别是关于一种加氏乳杆菌TCI515或其代谢产物用于制备免疫调节组合物的用途。本发明提供免疫调节益生菌株，是寄存编号为DSM33105的加氏乳杆菌及加氏乳杆菌或其代谢产物用于制备免疫调节组合物的用途。该益生菌株及其代谢产物能增强先天免疫力调节基因的表现，并且在发炎反应被诱发的情况下抑制促发炎细胞激素的基因表现，因此既可提升个体的先天免疫力，又可避免组织因过度发炎反应而受损。本发明亦提供一种包含该益生菌株的免疫调节组合物。
Description
技术领域
本发明是涉及微生物领域，特别是关于一种加氏乳杆菌TCI515或其代谢产物用于制备免疫调节组合物的用途。
背景技术
人体的免疫系统大致可分为「先天免疫」与「后天免疫」两部分。「先天免疫」系统是由非专一性免疫细胞与保护性蛋白质共同构成，其在病原体(例如细菌、病毒、霉菌、寄生虫等可引起疾病的微生物) 通过皮肤或黏膜而进入人体时启动。此时，具有吞噬微生物能力的白血球，例如嗜中性白血球、分化自单核细胞的巨噬细胞等会聚集于病原体入侵处以消灭该病原体。包含白血球在内的某些细胞还会分泌促发炎细胞激素，召集更多的白血球至病原体所在处。同时，自然杀手细胞也会参与围剿，负责毒杀被病原体感染的细胞。此外，体液中也会进行补体蛋白活化以攻击病原体。
当个体免疫力变弱时，疾病便容易发生，例如频繁地出现感冒症状，甚至有较高风险罹患癌症。然而，免疫系统保护身体免于病原入侵是有代价的，当身体因为免疫系统调节失灵而处于慢性发炎状态，体内的正常细胞或组织便会受损害，严重者可能缩短平均寿命。因此，使身体免疫系统处于平衡状态是维持健康的重要原则之一。
已知维系免疫系统正常功能方法包括日常饮食注意营养均衡、避免肥胖、维持规律作息、适度运动、保持心情愉悦等。然而，对于学业繁重或工作忙碌的现代人而言，恪守健康生活习惯有实行上的困难。因此，开发一种方便使用且有助于维持免疫平衡的新颖组合物，以达到减少疾病发生及长寿的目标，实有其必要。
发明内容
缘此，本发明的一目的在提供一种免疫调节益生菌株，其是可供食用的加氏乳杆菌(Lactobacillus gasseri)的新颖菌株。该菌株是寄存于DSMZ-德国微生物保藏中心，其寄存标号为DSM33105。
本发明的另一目的在提供一种前述加氏乳杆菌或其代谢产物用于制备免疫调节组合物的用途。
在本发明的一实施例中，该加氏乳杆菌或其代谢产物提高先天免疫力。此作用可归因但不限于该加氏乳杆菌或其代谢产物增强介白素-1β(interleukin 1 beta，IL-1β)、肿瘤坏死因子-α(tumor necrosis factor alpha，TNF-α)、介白素-8 (interleukin-8，IL-8)、介白素-18(interleukin-18，IL-18)、或其任意组合的基因表现。
在本发明的一实施例中，该加氏乳杆菌或其代谢产物抑制一发炎反应。该发炎反应是可由一病原体或其所产生物质如脂多糖(lipopolysaccharide，LPS) 所引发。此作用可归因但不限于该加氏乳杆菌或其代谢产物在该发炎反应时抑制介白素-18、肿瘤坏死因子-α、或其组合的基因表现。
本发明的又一目的在提供一种免疫调节组合物，包含一有效量的加氏乳杆菌或其代谢产物，其中该加氏乳杆菌的寄存编号为DSM33105。
本发明揭示的加氏乳杆菌及其代谢产物能增强先天免疫力调节基因的表现，因此有助于提升个体的先天免疫力以对抗外来病原体入侵。此外，该菌株及其代谢产物在发炎反应被诱发的情况下抑制促发炎细胞激素的基因表现，因此能避免组织或器官因过度发炎反应而受损。是故，加氏乳杆菌DSM33105 可用于制备免疫调节组合物。该组合物可具有粉末、颗粒、溶液、或胶体的剂型，且可制成食品、饮品、营养补充剂、或医药品，藉由口服方式给予一个体。
以下将配合图式进一步说明本发明的实施方式，下述所列举的实施例是用以阐明本发明的发明特点及应用，而非以限定本发明的范围，任何熟习此技艺者，在不脱离本发明的精神和范围内，当可做些许更动与润饰，因此本发明的保护范围当视后附的申请专利范围所界定者为准。
附图说明
图1显示人类单核细胞株THP-1以乳杆菌培养基(MRSD)或多种加氏乳杆菌培养物上清液处理后，其IL-1β基因的相对表现量柱形图；
图2显示人类单核细胞株THP-1以MRSD培养基或指定加氏乳杆菌培养物上清液处理后，其TNF-α基因的相对表现量柱形图；
图3显示人类单核细胞株THP-1以MRSD培养基或指定加氏乳杆菌培养物上清液处理后，其IL-8基因的相对表现量柱形图；
图4显示人类单核细胞株THP-1以MRSD培养基或指定加氏乳杆菌培养物上清液处理后，其IL-18基因的相对表现量柱形图；
图5显示人类单核细胞株THP-1以MRSD培养基或指定加氏乳杆菌培养物上清液处理再与脂多糖(LPS)共培养后，其IL-18基因的相对表现量柱形图；
图6显示人类单核细胞株THP-1以MRSD培养基或多种加氏乳杆菌培养物上清液处理再与脂多糖(LPS)共培养后，其TNF-α基因的相对表现量柱形图；
图7显示本发明的加氏乳杆菌在人工胃液模拟试验中的菌数变化柱形图；
图8显示本发明的加氏乳杆菌在人工肠液模拟试验中的菌数变化柱形图。
具体实施方式
本发明提供一种具有免疫调节功效的加氏乳杆菌，其是分离自母乳，经培养及菌种鉴定后确认为一新颖菌株，实验编号TCI515，于2019年5月2日保藏于DSMZ-德国微生物保藏中心(German Collection of Microorganisms and Cell Cultures，DSMZ)，地址为德国布伦瑞克市38124因霍芬大街7B，寄存编号为DSM33105。以下实施例显示该菌株及其代谢产物能增强先天免疫力调节基因的表现，并且在发炎反应被诱发的情况下能抑制促发炎细胞激素的基因表现。
定义
本文中所使用数值为近似值，所有实验数据皆表示在20％的范围内，较佳为在10％的范围内，最佳为在5％的范围内。
本文中所谓「有效量」是指一活性物质在一个体引发特定功效所需要的量。如本技术领域熟习技艺者所认知，有效剂量将依给予途径、赋形剂的使用、以及与其它物质共享的可能而变化。
材料与方法
细菌培养
以下实施例使用分离自人类母乳且经16S rRNA基因序列比对而确定的加氏乳杆菌，包括寄存于DSMZ-德国微生物保藏中心(German Collection of Microorganisms andCell Cultures，DSMZ)的DSM33105菌株，其16S rRNA基因具有SEQ ID NO:1的核苷酸序列；以及LH009菌株及LH028菌株。各该细菌于解冻及活化后，依1％的接种量在37℃静置培养于乳杆菌属MRSD培养基(55g乳杆菌MRS肉汤(BD Difco Lactobacilli MRS Broth；ThermoFischer Scientific)，溶于1L去离子水，pH值约6.8)18小时。所得细菌培养物经过5000rpm离心20分钟后，收集上清液以供进一步分析。该上清液包含细菌代谢产物。
细胞培养
以下实施例使用购自美国典型培养物保存中心(American Type CultureCollection，ATCC)的人类单核细胞株(human monocytic cell line)THP-1(ATCC TIB-202)及人类大肠癌上皮细胞株(human colon adenocarcinoma cell line)CACO2(ATCCHTB-37)。THP-1细胞是在37℃、5％二氧化碳的条件下培养于添加10％胎牛血清(fetalbovine serum，FBS)及1％青霉素/链霉素的RPMI 1640培养基(Gibco RPMI medium 1640；Thermo Fisher Scientific)，以下称RPMI 细胞培养基。CACO2细胞是在37℃、5％二氧化碳的条件下培养于添加10％ FBS及1％青霉素/链霉素的DMEM培养基(Dulbecco's modifiedEagle’s medium；Thermo Fischer Scientific)，以下称DMEM细胞培养基。
基因表现量分析
基于定量聚合酶链锁反应(quantitative polymerase chain reaction，简称qPCR)测定THP-1细胞中有关调节先天免疫力的细胞激素的基因表现量，其步骤简述如下。依据厂商使用说明，利用RNA萃取套组(RNA Extraction Kit； Geneaid)自细胞分离出核糖核酸(RNA)，于37℃下以反转录酶
III Reverse Transcriptase(Invitrogen)将2000ng RNA反转录为cDNA。其后，利用 qPCR套组(KAPA CYBR FAST qPCRKit(2X)；KAPA Biosystems)以及目标基因与作为内部对照的甘油醛3-磷酸脱氢酶(Glyceraldehyde 3-phosphate dehydrogenase)基因GAPDH的引物对(表1)在PCR反应仪(Step One Plus Real-Time PCR system；Applied Biosystems)对前述cDNA进行qPCR，并分析 PCR产物的解链曲线(melting curve)。
表1
最终，使用2-ΔΔCT方法测定目标基因的相对表现量。该方法以GAPDH 基因的循环阈值(CT)作为内部对照的参考基因的循环阈值，按照以下公式计算相对倍数变化：
ΔCT＝实验组或控制组的目标基因的CT-内部对照的CT
ΔΔCT＝实验组的ΔCT-控制组的ΔCT
倍数变化＝2-ΔΔCt平均值
抗发炎功效试验中，基因表现量的测定是依前述方法进行，但使用TATA 框结合蛋白(TATA-box binding protein)基因TBP作为内部对照，其正向引物及反向引物的核苷酸序列分别为5’-GCCAGCTTCGGAGAGTTCTGGGATT -3’(SEQ ID NO:12)及5’-CGGGCACGAAGTGCAATGGTCTTTA-3’(SEQ ID NO:13)。
统计分析是使用Excel软件中的STDEV函数计算各基因相对表现量的标准偏差，并以单尾学生t检定(TTEST)判定统计上显著性。
实施例1
加氏乳杆菌对先天免疫力调节基因表现的增强作用
为评估本发明的加氏乳杆菌的免疫力增强作用，利用qPCR测定人类单核细胞株THP-1经指定加氏乳杆菌培养物上清液处理后，其先天免疫力调节基因的表现变化。简言之，将THP-1细胞依1×106个细胞/孔接种于6孔盘，各孔含有2mL RPMI细胞培养基。在37℃培养细胞3至6小时后，移除该培养基，并以下列方式处理各孔细胞：(a)施以2mL RPMI细胞培养基(控制组)；(b) 施以2mL含0.5mg/mL MRSD培养基的RPMI细胞培养基(MRSD组)；(c)施以2mL含0.5mg/mL LH009菌株培养物上清液的RPMI细胞培养基(LH009 组)；(d)施以2mL含0.5mg/mL LH028菌株培养物上清液的RPMI细胞培养基 (LH028组)；或(e)施以2mL含0.5mg/mL DSM33105菌株培养物上清液的 RPMI细胞培养基(DSM33105组)。前述各组细胞于37℃培养6小时后用于 qPCR分析。
图1显示前述各组细胞相对于控制组细胞的IL-1β基因的相对表现量；图 2显示前述各组细胞相对于控制组细胞的TNF-α基因的相对表现量；图3显示前述各组细胞相对于控制组细胞的IL-8基因的相对表现量；图4显示前述各组细胞相对于控制组细胞的IL-18基因的相对表现量；图中**及***分别表示相比控制组为p<0.01及p<0.001。依据图1、2、3及4，对细胞施予LH009、 LH028、或DSM33105菌株的培养物上清液明显提升IL-1β、TNF-α、IL-8、及IL-18等基因表现，特别以DSM33105菌株的效果最显著。鉴于IL-1β与TNF-α可整体性加强个体对病原体的先天免疫力，又IL-8可促进嗜中性白血球的聚集与吞噬作用，以及IL-18可增加自然杀手细胞活性，此结果说明加氏乳杆菌 DSM33105及其代谢产物有助于提升个体的先天免疫力。
实施例2
加氏乳杆菌在脂多糖刺激下对促发炎基因表现的抑制作用
为评估本发明的加氏乳杆菌的抗发炎作用，利用qPCR测定人类单核细胞株THP-1与指定加氏乳杆菌培养物上清液及诱导发炎的脂多糖(LPS)共培养后，其促发炎细胞激素基因的表现变化。简言之，将THP-1细胞依1×106个细胞/孔接种于6孔盘，各孔含有2mLRPMI细胞培养基。在37℃培养细胞3 至6小时后，移除该培养基，并以下列方式处理各孔细胞：(a)施以2mL RPMI 细胞培养基(控制组)；(b)施以2mL添加100ng/mL脂多糖的RPMI细胞培养基(LPS组)；(c)施以2mL含0.5mg/mL MRSD培养基的RPMI细胞培养基1 小时，再施以100ng/mL脂多糖(MRSD+LPS组)；(d)施以2mL含0.5mg/mL LH009菌株培养物上清液的RPMI细胞培养基1小时，再施以100ng/mL脂多糖(LH009+LPS组)；(e)施以2mL含0.5mg/mL LH028菌株培养物上清液的 RPMI细胞培养基1小时，再施以100ng/mL脂多糖(LH028+LPS组)；或(f)施以2mL含0.5mg/mL DSM33105菌株培养物上清液的RPMI细胞培养基1小时，再施以100ng/mL脂多糖(DSM33105+LPS组)。前述各组细胞于37℃培养3小时后用于qPCR分析。
图5显示前述各组细胞相对于控制组细胞的IL-18基因的相对表现量；图 6显示前述各组细胞相对于控制组细胞的TNF-α基因的相对表现量；图中*** 表示相比LPS组为p<0.001。依据图5及图6，单纯脂多糖的处理导致TNF-α与IL-18等促发炎细胞激素的基因表现增加。然而，同时对细胞施予DSM33105 菌株或LH0028菌株的培养物上清液明显抑制TNF-α与IL-18基因表现。相对地，LH009菌株的培养物上清液无此抑制效果。此结果说明加氏乳杆菌 DSM33105及其代谢产物在发炎刺激下能抑制发炎讯号生成，因此能减少组织或器官因过度发炎反应而受损。并且，此抗发炎功效非任何品种的加氏乳杆菌皆具备。
实施例3
加氏乳杆菌的耐酸与耐胆盐特性
为测试本发明的加氏乳杆菌能否抵抗胃部的酸性环境与肠道中的胆盐，将该菌株的隔夜培养菌液(菌量约为5x109 CFU/mL)用于人工胃液或肠液模拟试验。在人工胃液模拟试验中，该菌液依1％的添加量添加至人工胃液(0.2％氯化钠水溶液，pH 3)，并于37℃、50rpm震荡培养3小时。在人工肠液模拟试验中，该菌液依1％的添加量添加至人工肠液(含0.68％磷酸二氢钾及或0.3％胆盐 (oxgall)的水溶液，pH 6.8)，并于37℃、50rpm震荡培养3小时。作为对比，另设置对照组，是将本发明的加氏乳杆菌的菌液培养于pH 7且不含胆盐的 0.2％氯化钠或0.68％磷酸二氢钾水溶液。前述试验后所得菌液取100μL涂布于乳杆菌属MRS琼脂培养基，于37℃培养隔夜以计算菌数。
依据图7，本发明的加氏乳杆菌经过人工胃液(pH 3)内培养3小时的菌数与在pH 7下培养的菌数相当，菌数差异小于101CFU/mL，显示其具有耐胃酸性。依据图8，本发明的加氏乳杆菌经过人工肠液(0.3％胆盐)内培养3小时的菌数与在无胆盐环境下培养的菌数相当，菌数差异小于101CFU/mL,显示其对胆盐的耐受性。该些结果说明加氏乳杆菌DSM33105经由口服进入人体后得以在消化道中生存，因此能发挥免疫调节的效用。
实施例4
加氏乳杆菌的肠道定殖试验
为测试本发明的加氏乳杆菌固着于肠道的能力，利用人类大肠癌上皮细胞株Caco-2进行肠道定殖试验。简言之，将Caco-2细胞依1×104个细胞/孔接种于24孔盘，各孔含有1mL DMEM细胞培养基。在37℃培养细胞数天至形成一细胞单层后，以不含抗生素的DMEM培养基替换原培养基，再将自加氏乳杆菌DSM33105的隔液培养菌液收集得的该菌细胞以磷酸缓冲盐溶液 (phosphate buffered saline，PBS；Thermo Fischer Scientific)配制成一细菌悬浮液以用于感染Caco-2细胞(0.5mL/孔)约30分钟。其后，利用含0.05％Triton X-100的PBS溶液裂解Caco-2细胞，并将所得细胞裂解物连同附着于细胞表面或进入细胞的加氏乳杆菌涂布于乳杆菌属MRS琼脂培养基，于37℃培养 48小时以计算菌数。依据肠道定殖试验的结果，每个肠细胞上附着约33个加氏乳杆菌细胞(定殖率约为33)，显示加氏乳杆菌DSM33105经由口服进入人体后能稳定地附着于肠道。
综上所述，本发明揭示的加氏乳杆菌能提升个体的先天免疫力，并且具有抑制发炎反应的功效，因此可用于制备一免疫调节组合物。该组合物可具有粉末、颗粒、溶液、或胶体的剂型，且可制成食品、饮品、医药品、或营养补充剂，藉由口服方式给予一个体。
Claims (9)
1.一种加氏乳杆菌用于制备免疫调节组合物的用途，其中所述加氏乳杆菌的寄存标号为DSM33105，所述加氏乳杆菌经过pH 3的人工胃液内培养3小时的菌数与在pH 7下培养的菌数相当，其中所述加氏乳杆菌经过0.3％胆盐的人工肠液内培养3小时的菌数与在无胆盐环境下培养的菌数相当。
2.根据权利要求1所述的用途，其特征在于，所述组合物用于提高先天免疫力。
3.根据权利要求2所述的用途，其特征在于，所述组合物用于增强介白素-1β、肿瘤坏死因子-α、介白素-8、介白素-18、或其任意组合的基因表现。
4.根据权利要求1所述的用途，其特征在于，所述组合物用于抑制发炎反应。
5.根据权利要求4所述的用途，其特征在于，所述发炎反应是由脂多糖引起。
6.根据权利要求4所述的用途，其特征在于，所述组合物在用于该发炎反应时抑制介白素-18、肿瘤坏死因子-α、或其组合的基因表现。
7.一种免疫调节组合物，包含有效量的加氏乳杆菌，其中所述加氏乳杆菌的寄存编号为DSM33105。
8.根据权利要求7所述的组合物，具有粉末、颗粒、溶液、或胶体的剂型。
9.根据权利要求7所述的组合物，是医药品。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW108120168 | 2019-06-11 | ||
| TW108120168A TWI707689B (zh) | 2019-06-11 | 2019-06-11 | 免疫調節之益生菌株及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112063541A CN112063541A (zh) | 2020-12-11 |
| CN112063541B true CN112063541B (zh) | 2022-08-02 |
Family
ID=73658557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910777548.XA Active CN112063541B (zh) | 2019-06-11 | 2019-08-22 | 一种加氏乳杆菌tci515用于制备免疫调节组合物的用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112063541B (zh) |
| TW (1) | TWI707689B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112553125A (zh) * | 2020-12-28 | 2021-03-26 | 西南大学 | 一种益生菌模拟物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011118060A1 (ja) * | 2010-03-26 | 2011-09-29 | 株式会社明治 | 腸管免疫の抑制剤のスクリーニング方法 |
| WO2012149615A3 (en) * | 2011-05-04 | 2013-11-14 | Lb Bulgaricum Plc | Polybacterial preparation with health benefits: antioxidant effect, reduction of cholesterol concentration, anti-inflammatory immunomodulating effect and release of bioactive peptides inhibiting angiotensin-converting enzyme |
| WO2018013583A2 (en) * | 2016-07-11 | 2018-01-18 | The Brigham And Women's Hospital, Inc. | Medicinal vaginal lactobacillus cocktail |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100014523A (ko) * | 2007-02-22 | 2010-02-10 | 위르겐 슈레첸메이르 | 인간의 알레르기 반응을 예방, 억제 또는 제거하는 프로바이오틱 그램-양성 박테리아 |
| KR20170049216A (ko) * | 2015-10-28 | 2017-05-10 | 고려대학교 산학협력단 | 신규한 락토바실러스 가세리 균주 및 이의 용도 |
-
2019
- 2019-06-11 TW TW108120168A patent/TWI707689B/zh active
- 2019-08-22 CN CN201910777548.XA patent/CN112063541B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011118060A1 (ja) * | 2010-03-26 | 2011-09-29 | 株式会社明治 | 腸管免疫の抑制剤のスクリーニング方法 |
| WO2012149615A3 (en) * | 2011-05-04 | 2013-11-14 | Lb Bulgaricum Plc | Polybacterial preparation with health benefits: antioxidant effect, reduction of cholesterol concentration, anti-inflammatory immunomodulating effect and release of bioactive peptides inhibiting angiotensin-converting enzyme |
| WO2018013583A2 (en) * | 2016-07-11 | 2018-01-18 | The Brigham And Women's Hospital, Inc. | Medicinal vaginal lactobacillus cocktail |
Non-Patent Citations (3)
| Title |
|---|
| Differential modulation of innate immunity in vitro by probiotic strains of Lactobacillus gasseri;Diomira Luongo 等;《BMC Microbiology》;20131231;第13卷;第1-12页 * |
| Probiotic and anti-inflammatory potential of Lactobacillus rhamnosus 4B15 and Lactobacillus gasseri 4M13 isolated from infant feces;Nam Su Oh 等;《PLoS One》;20180214;第13卷(第2期);摘要，第1页第2段至第12页最后1段，图1-5 * |
| The consumption of two new probiotic strains,Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT 5711,boosts the immune system of healthy humans;Mónica Olivares 等;《INTERNATIONAL MICROBIOLOGY》;20061231;第9卷;第47-52页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112063541A (zh) | 2020-12-11 |
| TWI707689B (zh) | 2020-10-21 |
| TW202045193A (zh) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11723933B2 (en) | Composition of bacteroides thetaiotaomicron for immune modulation | |
| BR112020022749A2 (pt) | cepa de lactobacillus paracasei e uso da mesma | |
| JP6954563B2 (ja) | 代謝障害を処置するための低温殺菌アッカーマンシアの使用 | |
| TWI592487B (zh) | 新穎副乾酪乳桿菌副乾酪亞種ｋ５６ | |
| Bove et al. | Probiotic features of Lactobacillus plantarum mutant strains | |
| JP6630388B2 (ja) | ラクトバチルスプランタルムｔｃｉ３７８、およびそれを用いた脂肪の減少および胃腸機能の改善における使用 | |
| JP2009511469A (ja) | 脂肪代謝及び肥満に影響を及ぼすプロバイオティクス | |
| De Leblanc et al. | Effects of milk fermented by Lactobacillus helveticus R389 on immune cells associated to mammary glands in normal and a breast cancer model | |
| CN102792919A (zh) | 悉生动物肥胖模型的构建方法及其应用 | |
| JP2019508486A (ja) | 胃腸炎の処置及び予防のためのフィーカリバクテリウム・プラウスニッツィｃｎｃｍ ｉ−４５７３株 | |
| KR102297271B1 (ko) | 당뇨 및 고지혈증을 포함하는 대사성 질환의 예방 또는 치료 활성을 갖는 락토바실러스 람노서스 nbm 17-4 균주 | |
| GB2528342A (en) | Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases | |
| US20200078414A1 (en) | Method of preventing or treating obesity using a novel strain of parabacteroides goldsteinii | |
| JP5312322B2 (ja) | インターフェロンβ産生促進剤及びその製造法 | |
| CN112063541B (zh) | 一种加氏乳杆菌tci515用于制备免疫调节组合物的用途 | |
| Kaushal et al. | Age-related decline in macrophage and lymphocyte functions in mice and its alleviation by treatment with probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum | |
| TWI729384B (zh) | 泌尿生殖道保健之益生菌株及其用途 | |
| US20140348792A1 (en) | Methods to reduce polyposis and colorectal cancer | |
| JP5995593B2 (ja) | 抗炎症剤 | |
| Tobita et al. | Heat-treated Lactobacillus crispatus KT strains reduce allergic symptoms in mice | |
| JP2022513208A (ja) | がんを治療するためのｐａｒａｂａｃｔｅｒｏｉｄｅｓ細菌株を含む組成物 | |
| Saulnier et al. | Probiotics and small bowel mucosa: Molecular aspects of their interactions | |
| JP4479162B2 (ja) | 免疫機能調節剤および免疫機能調節食品 | |
| KR101761506B1 (ko) | 락토바실러스 펜토서스를 유효성분으로 포함하는 Th1-매개 면역 질환, Th17-매개 면역 질환, 또는 Th2-매개 면역 질환의 예방, 개선, 또는 치료용 조성물 | |
| WO2023001658A1 (en) | Probiotics for use in boosting the immune system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |